The Russian direct investment Fund (RDIF) and the pharmaceutical company “R-Pharm” intend to invest at least 4 billion rubles in the expansion of production of drugs for the treatment COVID-19, as well as the development of vaccines against coronavirus infection, writes Forbes.
According to the owner of “R-Pharm” Alexey Repik, soon his company and RDIF will set up a separate legal entity. Repik did not specify how distribution of shares in the new company, saying only that it would be about “equal partnership”.
One of the areas for investment will be the production of the drug olokizumab (Ortigia), developed “R-Pharm” initially for the treatment of rheumatoid arthritis. The drug is a monoclonal antibody that blocks directly interleukin-6. Rokyzana made to the existing guidelines of the Ministry of health therapy for coronavirus infection – it can be used to prevent cytokine storm, a powerful inflammatory reaction that often occurs when COVID-19.
Also, the partners intend to invest in a vaccine against coronavirus infection developed by the National research centre of epidemiology and Microbiology. N. F. Gamalei.
Repik said that the issue of organizing production of the vaccine “R-Pharm” interacts with the center Gamalei March 2020. According to him, the vaccine will be produced in the new building of the company “R-Pharm” in Yaroslavl. Repik also said that his company is in talks according to another embodiment of the vaccine, involving foreign companies.